Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8347174rdf:typepubmed:Citationlld:pubmed
pubmed-article:8347174lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8347174lifeskim:mentionsumls-concept:C0014792lld:lifeskim
pubmed-article:8347174lifeskim:mentionsumls-concept:C0005528lld:lifeskim
pubmed-article:8347174lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:8347174lifeskim:mentionsumls-concept:C0041917lld:lifeskim
pubmed-article:8347174pubmed:issue3lld:pubmed
pubmed-article:8347174pubmed:dateCreated1993-9-9lld:pubmed
pubmed-article:8347174pubmed:abstractTextThe transport of 5-fluorouracil (5-FU) and uracil into human erythrocytes has been investigated under initial velocity conditions with an "inhibitor-stop" assay using a cold papaverine solution to terminate influx. At 37 degrees and pH 7.3, 5-FU influx was nonconcentrative; was partially inhibited by adenine, hypoxanthine, thymine, and uracil; and was insensitive to inhibition by nucleosides or inhibitors of nucleoside transport. Inhibition of the influx of 5-FU or uracil by adenine (3.0 mM) did not increase when other pyrimidines or inhibitors of nucleoside transport were combined with adenine. 5-FU and uracil exhibited similar saturable (Km approximately 4 mM, Vmax approximately 500 pmol/sec/5 microL cells) and nonsaturable (rate constant approximately 80 pmol/sec/mM/5 microL cells) components of influx. 5-FU, uracil, adenine, and hypoxanthine were competitive inhibitors of each other's influx with Ki values matching their respective Km values for influx. We conclude that 5-FU and uracil enter human erythrocytes at similar rates via both nonfacilitated diffusion and the same carrier that transports adenine and hypoxanthine.lld:pubmed
pubmed-article:8347174pubmed:languageenglld:pubmed
pubmed-article:8347174pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:citationSubsetIMlld:pubmed
pubmed-article:8347174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8347174pubmed:statusMEDLINElld:pubmed
pubmed-article:8347174pubmed:monthAuglld:pubmed
pubmed-article:8347174pubmed:issn0006-2952lld:pubmed
pubmed-article:8347174pubmed:authorpubmed-author:ZimmermanT...lld:pubmed
pubmed-article:8347174pubmed:authorpubmed-author:DominB ABAlld:pubmed
pubmed-article:8347174pubmed:authorpubmed-author:MahonyW BWBlld:pubmed
pubmed-article:8347174pubmed:issnTypePrintlld:pubmed
pubmed-article:8347174pubmed:day3lld:pubmed
pubmed-article:8347174pubmed:volume46lld:pubmed
pubmed-article:8347174pubmed:ownerNLMlld:pubmed
pubmed-article:8347174pubmed:authorsCompleteYlld:pubmed
pubmed-article:8347174pubmed:pagination503-10lld:pubmed
pubmed-article:8347174pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:meshHeadingpubmed-meshheading:8347174-...lld:pubmed
pubmed-article:8347174pubmed:year1993lld:pubmed
pubmed-article:8347174pubmed:articleTitleTransport of 5-fluorouracil and uracil into human erythrocytes.lld:pubmed
pubmed-article:8347174pubmed:affiliationDivision of Experimental Therapy, Wellcome Research Laboratories, Research Triangle Park, NC 27709.lld:pubmed
pubmed-article:8347174pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8347174pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8347174lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8347174lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8347174lld:pubmed